CClinicalTrials.gg
CompletedNCT02812550Updated Jun 24, 2016

Full-spectrum Endoscopy in Colorectal Cancer Screening

An interventional study of colonoscopy procedure in Colorectal Cancer, sponsored by Hospital del Rio Hortega. Completed. Open to participants aged 50 Years to 69 Years. Per ClinicalTrials.gov, last updated 2016-06-24.

Sponsored by Hospital del Rio Hortega · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
50 Years to 69 Years
Sex
All
01

Study summary

The purpose of this study is to compare the adenoma detection rates of full-spectrum endoscopy versus standard forward-viewing colonoscopy in colorectal cancer screening programme.

Read the detailed description

Colorectal cancer is the third most common neoplasia and the second leading cause of cancer death in West countries. Colonoscopy is the gold standard for prevention of colorectal cancer disease. Screening for colorectal cancer with biennial faecal occult blood testing is a widely used strategy followed by colonoscopy for those with a positive test. Colonoscopy identifies polyps during the procedure as well as polyp removal in order to prevent progression to cancer. Although, interval cancer appears after a colonoscopy because of 22-28% of polyp missed rates. Advanced Technology may improve adenoma detection rates so decrease interval cancer and reduce mortally. Full-spectrum endoscopy with 330º angle vision decrease adenoma miss rate in general population.

The investigators conducted a randomized trial in patients from colorectal cancer screening programme (aged 50-69 years) after faecal immunological test positive. One arm the colonoscopy is performed with standard forward view colonoscopy (170º angle view) and the other arm is performed with full-spectrum endoscopy (EndoChoice) (330º angle view)

02

Conditions studied

  • Colorectal Cancer

Keywords

  • full-spectrum endoscopy
  • polyp detection rate
  • colorectal cancer
  • colorectal screening
  • adenoma detection rate
  • endoscopic innovations
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's enrollment of 249 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Hospital del Rio Hortega is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patient referred for colorectal cancer screening with positive fecal inmunological test.
  • Age between 50 and 69 years

Exclusion criteria

Exclusion Criteria:

  • history of colonic resection,
  • high risk for colorectal cancer like family history of colorectal cancer o polyposis syndrome,
  • inflammatory bowel disease,
  • patients with lower gastrointestinal bleeding symptoms,
  • acute diverticulitis,
  • colonic strictures,
  • poor bowel preparation (Boston scale less than 5 points)
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
249 participants (actual)

Study arms

  • Other
    full-spectrum colonoscopy

    Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)

    Procedure: colonoscopy procedure

  • Other
    standar forward-viewing colonoscopy

    Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)

    Procedure: colonoscopy procedure

Interventions

  • Procedurecolonoscopy procedure

    endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy

06

What researchers measure

Primary outcomes

  1. adenoma detection rate in the two different colonoscopies

    number of colonoscopies at wich one or more histologically confirmed adenomas were found divided by the total number of colonoscopies performed in the same time period.

    Time frame: one week

Secondary outcomes

  1. time to caecal intubation in each group

    time to reach appendicular orifice

    Time frame: one week

  2. total procedure time in each group

    time since the begining of the procedure till is totally finish

    Time frame: one week

  3. Adverse events

    Any inmediatly complication

    Time frame: one week

  4. advance adenoma rate in each group

    10mm or greater in size, villous component or high grade dysplasia

    Time frame: one week

  5. polyp detection rate in right and left colon in each group

    Time frame: one week

  6. polyp retrieval rate in each group

    proportion of resected polyps that were retrieved and sent for histologically analysis

    Time frame: one week

  7. caecal intubation rate in each group

    proportion of all colonoscopic procedures in which the caecum, terminal ileum was reached

    Time frame: one week

  8. colonoscopy withdrawal time

    average time taken withdraw the colonoscope from the caecal pole to the anus.

    Time frame: one week

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Nunez-Rodriguez H, Diez-Redondo P, Perez-Miranda M, Gonzalez Sagrado M, Conde R, De la Serna C. Role of Full-spectrum Endoscopy in Colorectal Cancer Screening: Randomized Trial. J Clin Gastroenterol. 2019 Mar;53(3):191-196. doi: 10.1097/MCG.0000000000000975. PubMed 29283904 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02812550
Lead sponsor
Hospital del Rio Hortega
Responsible party
Mª Henar Núñez Rodriguez (Dra Mª Henar Núñez Rodriguez, Hospital del Rio Hortega) — Principal investigator
First posted
Jun 24, 2016
Start date
May 2015
Primary completion
May 2016
Completion
Jun 2016
Last update
Jun 24, 2016

Study contacts

Mª Henar Núñez Rodriguez, MD, PhD
principal investigator · Hospital del Rio Hortega Valladolid, Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion